SCHEMBL8288204

SCHEMBL8288204

CC(C)(C)OC(=O)N1CCCC1CNc1nc(-c2ccccc2)no1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.48
OPRD1 P41143 1/20 0.47
MCHR1 Q99705 1/20 0.44
USP30 Q70CQ3 3/20 0.44
GPR119 Q8TDV5 3/20 0.44
KDM1A O60341 1/20 0.43
HDAC4 P56524 3/20 0.43
HDAC6 Q9UBN7 2/20 0.43
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
TSHR P16473 1/20 0.42
KMT2A Q03164 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ACKR3 P25106 1/20 0.41
POLB P06746 1/20 0.41
KDM4E B2RXH2 1/20 0.40
PKM P14618 1/20 0.40
HSD11B1 P28845 1/20 0.40
CPT1A P50416 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4958769 0.89 GRM5 (0.51)
SCHEMBL14282800 0.89 USP30 (0.52) USP30POLB
SCHEMBL4954742 0.89 USP30 (0.52) USP30POLB
SCHEMBL8288202 0.89 GRM5 (0.51)
SCHEMBL4953572 0.88 GPR119 (0.44) PRMT5OPRD1GPR119HDAC4HDAC6
SCHEMBL8288207 0.88 GPR119 (0.44) PRMT5OPRD1GPR119HDAC4HDAC6
SCHEMBL4954866 0.87 GRM5 (0.46) PRMT5OPRD1KDM1APOLB
SCHEMBL8290315 0.87 GRM5 (0.46) PRMT5OPRD1KDM1APOLB
SCHEMBL29070 0.83 GPR119 (0.51) USP30GPR119ALDH1A1KMT2AL3MBTL1
SCHEMBL29071 0.83 GPR119 (0.51) USP30GPR119ALDH1A1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080027035-A1 Dpp-Iv Inhibitors GRAFFINITY PHARMACEUTICALS AG (DE) 2008-01-31 US disclosed
US-20080027035-A1 Dpp-Iv Inhibitors GRAFFINITY PHARMACEUTICALS AG (DE) 2008-01-31 US disclosed
EP-1613304-B1 DPP-IV INHIBITORS SANTHERA PHARMACEUTICALS CH (CH) 2007-09-12 EP disclosed
WO-2005056003-A1 DPP-IV INHIBITORS SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) 2005-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027035-A1 Dpp-Iv Inhibitors DPP4, DPP7, DPP3 PRMT5 200/4885OPRD1 1248/4885MCHR1 3024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.